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We show by x-ray crystallography that the complex trans, trans,
trans-[Pt(N3)2(OH)2(NH3)(py)] (1) contains an octahedral PtIV center
with almost linear azido ligands. Complex 1 is remarkably stable in
the dark, even in the presence of cellular reducing agents such as
glutathione, but readily undergoes photoinduced ligand substitu-
tion and photoreduction reactions. When 1 is photoactivated in
cells, it is highly toxic: 13–80 x more cytotoxic than the PtII
anticancer drug cisplatin, and ca. 15 x more cytotoxic toward
cisplatin-resistant human ovarian cancer cells. Cisplatin targets
DNA, and DNA platination levels induced in HaCaT skin cells by 1
were similar to those of cisplatin. However, cisplatin forms mainly
intrastrand cis diguanine cross-links on DNA between neighboring
nucleotides, whereas photoactivated complex 1 rapidly forms
unusual trans azido/guanine, and then trans diguanine PtII ad-
ducts, which are probably mainly intrastrand cross-links between
two guanines separated by a third base. DNA interstrand and
DNA–protein cross-links were also detected. Importantly, DNA
repair synthesis on plasmid DNA platinated by photoactivated 1
was markedly lower than for cisplatin or its isomer transplatin (an
inactive complex). Single-cell electrophoresis experiments also
demonstrated that the DNA damage is different from that induced
by cisplatin or transplatin. Cell death is not solely dependent on
activation of the caspase 3 pathway, and, in contrast to cisplatin,
p53 protein did not accumulate in cells after photosensitization of
1. The trans diazido PtIV complex 1 therefore has remarkable
properties and is a candidate for use in photoactivated cancer
chemotherapy.
cytotoxicity  DNA binding  photochemistry  cisplatin
Traditional platinum-based anticancer compounds are a clin-ically successful group of therapeutic agents; however, their
use is constrained by dose-limiting side-effects and the problem
of acquired resistance (1). To avoid these problems, we are
exploring the use of inert, nontoxic platinum complexes that can
be activated locally in cancer cells with light (2). In general,
photoactivation offers potential for initiating unusual ligand
substitution and redox reactions of transition metal complexes
(3, 4), and hence photoactivation may offer new mechanisms of
anticancer activity.
The light-activated PtIV complex described here is effective in
killing human cancer cells, including cisplatin-resistant cells, but
only upon irradiation, thus combining the potent cytotoxic
ability of platinum compounds with the selectivity of a light-
activated drug. Photodynamic therapy (PDT) uses photosensi-
tizers such as porphyrins, which require oxygen to kill cancer
cells via the formation of singlet oxygen. This can be a problem
due to the hypoxic nature of manymalignant andmost aggressive
tumors (5); therefore, photoactivatable complexes that do not
require oxygen may be more effective. Light-activated drugs are
routinely used in treatment of nonmelanoma skin cancers and
benign hyperproliferative diseases of the skin, as well as tumors
of the brain, lung, esophagus, bladder, pancreas, and bile duct (6).
Platinum(IV) diazido complexes containing cis-diam(m)ine
ligands are relatively inert in the dark, even in the presence of
millimolar concentrations of the intracellular reducing agent
glutathione (7–9). We report here the dramatic effects arising
from incorporation of a -acceptor pyridine ligand in place of an
ammine ligand. Trans, trans, trans-[Pt(N3)2(OH)2(NH3)(py)] (1)
is highly phototoxic and reacts with guanine derivatives and with
DNA to give unusual PtII adducts not readily formed in the
absence of light.
Results
Stability and Photochemistry. The all-trans geometry of 1 deter-
mined by x-ray crystallography is shown in Fig. 1. The extensive
hydrogen bonding network in the crystals is shown in supporting
information (SI) Fig. 5. Complex 1 (or 15N-1, 3 mM) was very
stable in water and did not react with 5 GMP (2 mol equiv) in
the absence of light over a period of 5 months as judged by
NMR spectroscopy. Complex 1 was also relatively stable to
reduced glutathione (2 mol equiv), with only 5% of PtIV
reduced to PtII after 21 d.
UVA irradiation (365 nm) of an aqueous solution of 1 gave a
decrease in intensity of the azide-to-PtIV charge-transfer band at
289 nm (Fig. 2A), indicating loss of the PtIV–azide bonds.
After irradiation of an aqueous solution of 15N–1, very little
reduction to PtII was observed by 1D 1H and 2D [1H,15N] HSQC
NMR spectroscopy. Two of the PtIV photoproducts were iden-
tified as the tetrahydroxy complex trans-[Pt(OH)4(15NH3)(py)]
(2) and the monoazide-trihydroxy complex trans-
[Pt(N3)(OH)3(15NH3)(py)] (3) (SI Fig. 6). Neither 1D 1H nor 2D
[1H,1H] COSY NMR spectroscopy gave evidence for release of
pyridine from the platinum center. However, subsequent work
showed that the presence of nucleophilic biomolecules has a
major influence on the photoreaction pathways.
After only 1 min of UVA irradiation of 15N-1 in the presence
of 2 mol equiv 5-GMP, a new 2D [1H,15N] HSQC NMR peak
for a PtII species (4) appeared (Fig. 2B). Further irradiation led
to the appearance of another new PtII peak (5). The PtII peaks
were assigned as (SP-4-4)-[Pt(N3)(15NH3)(py)(5-GMP)] (4)
(1H,15N) 4.15, 66.37, and trans-[Pt(15NH3)(py)(5-GMP)2]2
(5) (1H,15N) 4.42, 65.63 (confirmed by their synthesis, see SI
Text). The peak for 4 decreased in intensity upon further
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irradiation, consistent with light-induced loss of the second azido
ligand, whereas the concentration of the bis-GMP adduct 5
increased (Fig. 2C). Platinum binding to N7 of 5-GMP was
confirmed both by the low-field 1H NMR shift of H8 (10), and
by a 1H NMR pH titration (absence of H8 chemical shift change
associated with N7 protonation, pKa  2.5 (11) for both PtII
photoproducts 4 and 5, SI Fig. 7).
Remarkably, the photoreaction with 15N-1 and 5-GMP was
also induced by red laser light (647.1 nm) despite the low power
(15 mW), and very low absorbance at this wavelength (647 
10 M1cm1; SI Fig. 8). Peaks corresponding to both 4 and 5
appeared after 2.5 h of irradiation.
Phototoxicity. Complex 1 reduced the viability of HaCaT kera-
tinocytes, cisplatin-sensitive A2780, and cisplatin-resistant
A2780cis human ovarian carcinoma cells in a dose-dependent
manner when photoactivated with UVA (Fig. 3 and Table 1), but
was not cytotoxic to HaCaT or A2780cis cells in the dark. A2780
cells were 80-fold more sensitive to photoactivated 1 compared
with cisplatin under identical conditions, followed by keratino-
cytes (24-fold) and A2780cis cells (15-fold). Cisplatin itself
showed no difference in potency regardless of whether it was
irradiated. Complex 1 was also photoactive in SH-SY5Y neuro-
blastoma cells (IC50UVA: 2.4 M; IC50UVA: 244 M; data
not shown).
When irradiated with visible light (max 420 nm), the complex
was as potent as cisplatin under similar conditions (IC50 1  5
J/cm2 TL03: 85.8 M; Fig. 3D), despite very weak absorption by
1 in this part of the spectrum.
DNA Damage in Cells.When HaCaT cells were exposed to 5 J/cm2
UVA, DNA damage, as measured by migration of DNA from
the nucleus in the single cell gel electrophoresis assay, did not
change compared with an unirradiated control (2.5  0.4% and
3.1  0.2% DNA in comet tail, respectively). Pretreatment with
cisplatin significantly inhibited HaCaT cell DNAmigration after
H2O2 treatment in a dose-dependent manner by a maximum of
60% (SI Fig. 9). Transplatin also inhibited DNAmigration, but
was not cytotoxic to HaCaT cells under these conditions (data
not shown).
When complex 1 was photoactivated, a similar dose-
dependent decrease in DNA migration due to the formation of
cross-links was expected. However, a significant decrease in
DNA migration was noted only at doses of 12.2 M or higher.
This is at least twice the IC50 value of the drug in these cells, and
a highly phototoxic dose. In the dark, 1 had no effect on DNA
migration except at the highest dose (24.4 M).
Caspase Activity. The concentration of 1 used in these experi-
ments was determined from the dose-response plots of photo-
toxicity and produced 10%, 50% and 90% cell-kill 24 h after
irradiation. Caspase 3 and 7 activity could not be detected by the
Caspase-Glo assay either immediately after photoactivation of 1,
or 24 h after (corresponding to neutral red assay time point; SI
Fig. 10). In contrast, cisplatin treatment resulted in an increase
in luminescence corresponding to caspase activation.
PolyADP Ribose Polymerase and p53.Western blotting showed that
polyADP ribose polymerase, a known substrate of caspase 3, was
cleaved during treatment of A2780 cells with cisplatin, but not
with photoactivated 1. Cleavage was observed only when high
Fig. 1. X-ray crystal structure of 1. Selected bond lengths (Å) and angles (°):
Pt-N(1) 2.059(4); Pt-N(2) 2.020(4); Pt-N(3) 2.044(3); Pt-N(21) 2.046(3); N(11)–
N(12) 1.203(5); N(12)–N(13) 1.139(6); N(21)–N(22) 1.216(5); N(22)–N(23)
1.138(5); N(11)–N(12)–N(13) 174.4(5); N(21)–N(22)–N(23) 175.9(5).
Fig. 2. Photoreactions of 1. (A) UV-visible spectra recorded after 0, 1, 5, 15,
30, and 60 min of UVA irradiation. (B) Two-dimensional [1H,15N] HSQC NMR
spectra for 15N-1 and 2 mol equiv 5-GMP after 1 and 30 min of irradiation.
*, 195Pt satellites. (C) Decrease in concentration of 1 and formation of 4 and 5
with increasing irradiation time.
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doses of 1 were used and the cells were essentially dead (SI Fig.
11). It was evident that p53 is not detectable in cells 24 h after
treatment with photoactivated 1, in contrast to cisplatin (SI
Fig. 11).
Platination of DNA in Cells. The Pt content of DNA isolated from
HaCaT cells treated with 24.4 M complex 1 and irradiated
(UVA, 5 J/cm2) was determined (by ICP-MS) to be 0.35  0.05
ng Pt/g DNA, a level similar to that after treatment with
four-times higher dose of cisplatin [0.60 0.39 (range 0.21–0.98)
ng Pt/g DNA; see SI Text].
DNA Binding. Two sets of samples of CT DNA were treated with
1. One set was irradiated with UVA light immediately after
addition of 1, the other kept in the dark. The nonirradiated
samples contained no bound Pt even after 7 h, whereas the
amount of Pt bound to DNA in the irradiated samples increased
with time (SI Fig. 12). After 1 min, 50% of the Pt was bound and
this reached a plateau after5 h of continuous irradiation (87%
bound). When 1 was irradiated for 2 h and then added to DNA,
the amount of bound Pt plateaued after only 90 min and was
significantly lower (33%). Interestingly, when 1 was irradiated
for 2 h, left in the dark for 2 h and then added to DNA,
considerably less (26%) was bound to DNA even after 7 h (data
not shown).
Transcription Mapping of DNA Adducts in Vitro. Experiments on in
vitro RNA synthesis by T7 RNA polymerase were carried out
using a linear 212-bp DNA fragment (SI Fig. 13A), treated with
1 (in the dark or under irradiation conditions) for 5 h. The major
stop sites produced by the irradiated template treated with 1 (SI
Fig. 13B, lane 1Irrad) were similar to those produced by trans-
platin (SI Fig. 13B, lane Transplatin); no stop sites were pro-
duced by templates treated with 1 in the dark (SI Fig. 13B, lane
1Dark). The stop sites produced by the irradiated template
treated with 1 and transplatin were less regular and appeared
mainly at single guanines and cytosines (i.e., at the preferential
DNA binding sites of transplatin and several antitumor ana-
logues of this PtII complex; refs. 12–14) and to a considerably less
extent also at adenine sites.
Characterization of DNA Adducts. Ethidium bromide is a fluores-
cent probe used to characterize perturbations induced in DNA
by bifunctional adducts of several Pt compounds (15, 16). The
cross-links formed in double-helical DNA by a Pt complex
prevent ethidium intercalation so that fluorescence is decreased
in comparison with unplatinated double-helical DNA. The de-
crease of fluorescence caused by the adducts of photoactivated
1 was markedly more pronounced than that caused by the DNA
adducts formed by cisplatin or transplatin in the dark at equiv-
alent rb (SI Fig. 14).
Thiourea labilizes monofunctionally bound transplatin and its
analogs from DNA (17–19), whereas bifunctional adducts are
resistant (17). Thiourea displaced 16 and 13% of photoacti-
vated 1 from DNA after 1 and 5 h, respectively, of reaction of 1
with DNAunder irradiation conditions. It can be concluded that,
Fig. 3. Phototoxicity of complex 1. Human HaCaT
keratinocytes (A), A2780 human ovarian carcinoma
cells (B), and A2780cis cisplatin-resistant cells (C) were
exposed to 5 J/cm2 filtered UVA or sham irradiated. (D)
HaCaT keratinocytes exposed to 5 J/cm2 filtered TL03
visible light (max 420 nm). The viability of cells treated
with TL03 radiation alone was 111.4%. Open symbols,
sham–irradiated samples; filled symbols, irradiated
samples; circles, complex 1; squares, cisplatin.
Table 1. IC50 values (M) of complex 1 and cisplatin with and without UVA irradiation
IC50 value, M*
HaCaT A2780 A2780cis
365 nm Dark 365 nm Dark 365 nm Dark
Complex 1 6.1 (5.6–6.6) 244.3† (NA) 1.9 (1.7–2.0) 244.3 (NA) 16.9 (11.7–24.7) 244.3 (NA)
Cisplatin 144.0 (124–166) 173.3 (153–196) 151.3 (133–173) 152.0 (137–168) 261.0 (214–319) 229.0 (191–274)
NA, not applicable.
*Goodness of fit monitored byR2 value and 95% confidence intervals (parentheses). Curves withR20.8 rejected. Each value is mean of two to three independent
experiments. Viability of cells treated with UVA light alone: 93.5  7.6% (HaCaT); 96.1  14.6% (A2780) and 84.3  7.7% (A2780cis).
† indicates IC50 outside concentration range used.






at these time intervals, 84–87% of monofunctional adducts of
photoactivated 1 had evolved to bifunctional lesions (SI Fig. 15).
DNA Interstrand Cross-Linking. The DNA interstrand cross-linking
efficiency was investigated by treating a linearized plasmid
pSP73 with 1, and then irradiating or storing in the dark. The
dark sample contained no bound Pt; in contrast a band corre-
sponding to interstrand cross-linked fragments, which migrate
more slowly, was seen for irradiated samples. The intensity of this
band increased with increasing irradiation time. After 5 h, the
frequency of interstrand CLs for 1 was 6%, compared with 4%
for cisplatin and transplatin (12) (SI Fig. 16).
DNA–Protein Cross-Linking.An ability to formDNA-protein cross-
links potentiates the cytotoxic effects of some antitumor Pt
complexes (20). We found that photoactivation of 1 readily
induces cross-links between duplex DNA (21 or 40 base pairs)
and the proteins KF histone H1, and NF-B (SI Fig. 17).
DNA Repair Synthesis.DNA repair synthesis by a repair-proficient
HeLa CFE in a pUC19 plasmid modified by 1 and UVA light
(rb  0.05), was monitored by measuring the amount of incor-
porated radiolabeled nucleotide. Considerably lower levels of
damage-induced DNA repair synthesis were detected in the
plasmid treated with 1 and UVA light in comparison to those
detected in the plasmid treated with cisplatin or transplatin in the
dark (Fig. 4).
Discussion
Stability and Photochemistry of 1. Complex 1 is remarkably stable
in the dark, and reacted only very slowly with reduced glutathi-
one over a period of several weeks. Such stability is important for
a potential photochemotherapeutic agent, so that it can reach
target sites before photoactivation. Two of the main photoprod-
ucts from irradiation of aqueous 15N-1 arose from azide substi-
tution by hydroxide: trans-[PtIV(OH)4(15NH3)(py)] (2) and trans-
[PtIV(N3)(OH)3(15NH3)(py)] (3), very little reduction of PtIV to
PtII was observed. However, in the presence of guanine (5-
GMP), the initial main photoproduct was the PtII monoazido
species [PtII(N3)(15NH3)(5-GMP)(py)] (4), which suggests that
the azide ligands do not leave the Pt center via a concerted
mechanism. In similar reactions of the trans diazido diammine
complex trans, trans, trans-[Pt(N3)2(OH)2(15NH3)2] with 5-GMP
(21), the analogous monoazido species (trans-[PtII(N3)(15NH3)2(5-
GMP)]) was not a product. This difference in photochemical
behavior compared with 1may contribute to the vastly increased
phototoxic potency of 1. The bis-5-GMP adduct trans-
[Pt(15NH3)(py)(5-GMP)2]2 (5) is rapidly formed from 1 upon
irradiation (5 min). The analogous complex trans-
[Pt(NH3)2(5-GMP)2]2 is difficult to produce from reactions of
transplatin under normal conditions in aqueous solution because
the second hydrolysis step is very slow (22). This finding corre-
lates with the scarcity of interstrand cross-links involving coor-
dination of two G bases in trans positions for trans PtII diam-
(m)ine complexes (23), and with the inactivity of transplatin.
Phototoxicity. The neutral red phototoxicity assay has been
validated against in vivo human reference data (24), and is
designed to compare the toxicity of a drug plus light compared
with either alone. The protocol prescribes a very short contact
time of the cells with test compound followed by a short
irradiation with a low dose of light (equivalent to 15–60 min
on a typical U.K. midday). This is different from the constant
challenge methods (typically 96 h) used to investigate cytotox-
icity, but is more reflective of the conditions for use of light-
activated drugs. Complex 1 rapidly accumulates in cells during
the 60 min preincubation period. On photoactivation, complex
1 was much more effective at killing all three cell types than was
cisplatin, but unlike cisplatin was relatively nontoxic in the dark.
Encouragingly, complex 1 was 15 times more toxic to cisplatin-
resistant A2780cis cells than cisplatin.
Conventional Pt-based agents, despite being among the most
successful and most frequently prescribed anticancer drugs, have
severe dose limiting side-effects that can result in treatment
failure. Additionally, tumors can possess intrinsic resistance or
acquire resistance to these drugs. A Pt prodrug that is nontoxic
in the dark and activated only to the cytotoxic species when
irradiated by light of the appropriate wavelength could benefit
treatment outcomes and inhibit acquisition of resistance. The
rapid phototoxic effect of complex 1 might arise from a number
of mechanisms, including differences in the kinetics of cell
uptake of the prodrug compared with cisplatin, faster kinetics of
DNA reactivity of the activated complex, a different spectrum of
DNA adducts formed which are more cytotoxic to the cell, and
other intracellular targets that contribute to the lethal effect on
photoactivation.
DNA Damage in Cells. The single-cell gel electrophoresis assay is
well documented as detecting intra- and interstrand cross-links
(25). HaCaT cells were treated with a clastogen immediately
after the UVA-irradiation period. This produces DNA-strand
breaks that result in migration of 70–100% of DNA from the
cell nucleus. If the DNA is cross-linked, then movement is
antagonized, decreasing the amount of DNA that can migrate
(26). Treating cells with cisplatin or transplatin, even for a very
Fig. 4. In vitro repair synthesis assay of the extract prepared from the
repair-proficient HeLa cell line. Repair synthesis used as substrates nonmodi-
fied pBR322 plasmid and pUC19 plasmid nonmodifed (lane noPt) or modified
at rb  0.05 by cisplatin or transplatin in the dark (lanes cisPt and transPt,
respectively), or by complex 1 under irradiation conditions (lane 1). (A) Results
of typical experiment. (Upper) Photograph of the ethidium-stained gel.
(Lower) Autoradiogram of the gel showing incorporation of [-32P]dCMP. (B)
Incorporation of dCMP into plasmid modified by cisplatin, transplatin or
complex 1. For all quantifications, representing mean values of three separate
experiments, incorporation of radioactive material was corrected for the
relative DNA content in each band. Radioactivity associated with incorpora-
tion of [-32P]dCMP into DNA modified by cisplatin was taken as 100%.
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short time, results in the formation of DNA adducts that inhibit
DNA migration in the comet assay. However, transplatin is not
toxic to HaCaT or A2780 cells under our experimental condi-
tions, nor is it therapeutically active. Thus, the technique cannot
distinguish between types of cross-link unless additional enzymes
are incorporated into the experimental design.
Photoactivated 1 did not replicate the activity of cisplatin when
it was tested in the single-cell gel electrophoresis assay. There
was limited inhibition of DNA migration. Despite this, photo-
activated 1 is undoubtedly much more toxic than cisplatin;
therefore, these data suggest a difference in mechanism of
action.
Stabilization of p53 after genotoxic insult has also been used
as a marker of DNA damage. We found that in A2780 cells,
reported as having wild-type p53, the protein was stabilized and
accumulated in the presence of cisplatin but not with photoac-
tivated 1 during the time frame of our experiment.
Caspase Activity. The data suggest that cell death caused by
photoactivation of 1 is not solely dependent on activation of the
caspase 3 pathway. Irradiation of complex 1 did not stimulate
caspase 3 activity in any of the cell lines, in contrast to cisplatin.
In addition, polyADP ribose polymerase was cleaved during
cisplatin treatment, but not by photoactivated 1, unless the dose
was very high. We found that the level of p53 was stabilised in
the presence of cisplatin but not with photoactivated 1 (SI Fig.
11). Taken together, the cell data suggest differences in the
behavior of photoactivated 1 compared with cisplatin. The
complex is relatively unreactive to cells in the dark, but when
irradiated it is very toxic, killing cells (including cisplatin-
resistant cells), irrespective of their p53 status, by a mechanism
that appears different from cisplatin.
DNA Binding and Cross-Linking. The rate of Pt binding to double-
helical DNA treated with 1 and irradiated continuously by UVA
was relatively high compared with the binding of nonirradiated
cisplatin or transplatin (27). The binding experiments also
indicate that the photoreactions result in irreversible coordina-
tion of 1 to double-helical DNA, which also facilitates sample
analysis. Hence, it was possible to prepare the samples of DNA
modified by 1 at a preselected value of rb.
Platinum binding to DNA resulting from treatment of CT
DNA with 1 under conditions of continuous irradiation reached
a plateau after5 h. However, not all Pt in the reaction mixture
bound to DNA (SI Text). This observation might mean that the
rate of binding of irradiated 1 to DNA was slower than the rate
of transformation of photoactivated 1 into unreactive products.
We tested this hypothesis: 1was irradiated for 2 h and then added
to DNA (see above). The results support the view that free 1 in
the reaction mixture with DNA can be transformed by UVA
light into species incapable of reacting with DNA.
The transcription mapping indicates that 1 binds to DNA
under irradiation conditions at sites similar to those of trans-
platin, i.e., less regularly than cisplatin and mainly at single
guanines and cytosines (i.e., at the preferential DNA binding
sites of transplatin and several antitumor analogues of this PtII
complex; refs. 12–14), and to a considerably less extent also at
adenine sites. Considerable evidence suggests that the antitumor
efficacy of bifunctional platinum compounds is the result of the
formation of various types of inter- and intrastrand CLs; how-
ever, their relative efficacy remains unknown. The results of this
work are consistent with the view that 1 forms on DNA under
irradiation conditions only a few interstrand cross-links (6%).
Thus, it is reasonable to suggest that photoactivated 1 forms
mainly intrastrand cross-links on DNA, or possibly mainly
monofunctional adducts. The monofunctional adducts of pho-
toactivated 1 close to become bifunctional lesions with a con-
siderably higher rate than those of transplatin (only 10%
monofunctional adducts of transplatin incubated with DNA in
the dark for 1–5 h evolve to bifunctional lesions; refs. 17 and 19).
The ethidium fluorescence data suggest that the conformational
distortion induced in DNA by the adducts of irradiated 1 spans
more base pairs around the platination sites than the adducts of
cisplatin or transplatin, presumably due to enhanced formation
of more delocalized bifunctional adducts, such as 1,3-intrastrand
cross-links. The latter view is also corroborated by the results of
the TU experiments and by the fact that photoactivated complex 1
forms trans diguanine PtII adducts more readily than transplatin.
DNA Repair Synthesis. DNA adducts of photoactivated 1 induced a
much lower level of repair synthesis than the adducts of transplatin
or cisplatin (Fig. 4) suggesting less efficient removal fromDNA and
enhanced persistence of the adducts of the photoactivated 1 in
comparison with the adducts of transplatin or cisplatin. Thus, one
of the important factors contributing to the high cytotoxicity of
photoactivated 1 appears to be a resistance of its DNA adducts
to DNA repair.
Conclusions
The PtIV diazido complex trans, trans, trans-[Pt(N3)2(OH)2
(NH3)(py)] (1) is unreactive in the dark but a potent photo-
toxin when photoactivated. Photoactivated 1 forms trans G
adducts both with model G derivatives and with plasmid DNA.
DNA–protein cross-links also form readily, and DNA repair
synthesis on plasmid DNA platinated by photoactivated 1 is
markedly lower than for transplatin. Cell death was not solely
dependent on activation of the caspase 3 pathway, and, in
contrast to cisplatin, p53 protein did not accumulate in cells
after photosensitization of 1. Therefore the trans diazido PtIV
complex 1 has an unusual mechanism of action that differs
significantly from that of cis complexes. After the initial lack
of exploration of the anticancer activity of (nonphotoacti-
vated) trans Pt complexes because of the inactivity of trans-
platin, this is now a highly active field of research (28). It is
apparent from the work described here that photoactivated
trans PtIV complexes can exhibit remarkable cytotoxic prop-
erties. Complex 1 is a candidate for use in photoactivated
cancer chemotherapy.
Materials and Methods
NMR Spectroscopy. NMR spectra were recorded at 298 K on a Bruker spec-
trometer (1H: 500.13 MHz; 15N: 50.7 MHz). Samples were prepared in 90%
H2O/10% D2O with 1H shifts referenced internally to dioxane ( 3.764), and 15N
externally to 15NH4Cl (1 M) in HCl (1.5 M;  0). All data were processed with
XWIN-NMR software (version 3.6, Bruker).
Photochemistry. Photoreactions of aqueous solutions of complex 1 after UVA
irradiation were followed by UV-visible spectroscopy (0.05 mM) or 1D 1H and
2D [1H,15N] HSQC NMR spectroscopy (3 mM). For the latter, the pH was
adjusted to 5 with HClO4, and readjusted to 5  0.2 after each irradiation to
ensure slow exchange of NH protons (on PtIV).
Phototoxicity. Phototoxicity was assessed using the neutral red phototoxicity
assay. This is an industry standard test recommended by both the Food and
Drug Administration (FDA; ref. 24) and the European Agency for the Evalua-
tion of Medicinal Products (EMEA). The test is designed to compare the toxicity
of a drug plus light, compared with the drug alone. This also reflects the
conditions used for light-activated drugs. Typically, a clinical light treatment
lasts for 20–60 min. Complexes were dissolved in Earle’s balanced salt solution
and sterile-filtered (0.22 m) before being applied to cells. All experiments
were carried out in a specially adapted photobiology laboratory, with ambi-
ent light levels1 lux (Solatell). Cells were seeded at a density of7	 104 cells
per cm2 and left to adhere overnight. After washing cells with PBS, test
compounds were added in Earle’s solution and incubated for 1 h (37°C/5%
CO2). After this time, cells were irradiated (5 J cm2) with UVA. Following
irradiation, the salt solution was removed, the cells thoroughly washed, and
then returned to the incubator in complete growth medium. Phototoxicity
was determined 24 h later using neutral red uptake (29, 30). The amount of






test compound required to inhibit dye uptake by 50% (IC50 value) was deter-
mined by nonlinear regression (GraphPad Prism). Experiments were per-
formed in triplicate and each repeated two to three times, with chlorprom-
azine as positive control.
Single-Cell Gel Electrophoresis. Single-cell gel electrophoresis (comet assay)
was performed as described in ref. 21.
Caspase Activity.Caspase activity was monitored using a luminescent Caspase-
Glo 3/7 kit (Promega) according to the manufacturer’s instructions.
DNA Binding. Calf thymus (CT) DNA (32 g/ml) was incubated with 1 (8 M) in
10 mM NaClO4, 310 K. The value of ri (molar ratio of free Pt complex to
nucleotide phosphates at onset of incubation with DNA) was 0.08. Aliquots
were removed at various time intervals, quickly cooled on an ice bath and then
exhaustively dialyzed against 10 mM NaClO4 at 277 K in the dark to remove
free (unbound) Pt. The Pt content in these DNA samples (rb) was determined
by flameless atomic absorption spectroscopy. To determine whether the
photoproducts which bind to DNA are stable, 1 (16 M) was irradiated for 2 h
then divided into two parts; one was added to CT DNA immediately after the
irradiation, whereas the other was incubated for a further 2 h in the dark and
then added to DNA. Both parts were added to the same amount of CT DNA (64
g/ml) dissolved in 10 mM NaClO4 (ri  0.08) and further incubated at 310 K
in the dark for 7 h. The samples were then treated as described above.
TranscriptionMapping of DNAAdducts in Vitro. Transcription of the (NdeI/HpaI)
restriction fragment of pSP73KB DNA with DNA-dependent T7 RNA polymer-
ase and electrophoretic analysis of transcripts were performed according to
the recommended protocols (Promega Protocols and Applications, 43-46,
1989/90) and described in ref. 12.
DNA Repair Synthesis. Repair DNA synthesis of cell-free extract (CFE) was
assayed using pUC19 and pBR322 plasmids. A similar amount of undamaged
pBR322 of a slightly different size was included in the reactions to show the
background incorporation into undamaged plasmid. This background incor-
poration was subtracted from that for platinated pUC19.
For details of chemicals and biochemicals, synthesis and characterization of
complexes, and methods and techniques used, see SI Text.
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